Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Menu
Sign in
Sign in

MHRA Approves Nubeqa Treatment Combination for Advanced Form of Prostate Cancer

MHRA Approves Nubeqa Treatment Combination for Advanced Form of Prostate Cancer

Bayer’s Nubeqa (darolutamide) plus androgen deprivation therapy (ADT) in combination with docetaxel has received marketing authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of patients with metastatic hormone sensitive prostate cancer after the treatment showed a statistically significant 32.5 percent reduced risk of death.

Nubeqa works by blocking androgen receptors in cancer cells. Doing so blocks testosterone’s effects and inhibits the survival and proliferation of cancer cells.

The approval was made under Project Orbis, an international partnership that includes the U.S., Australia and other countries to accelerate review and approval of promising cancer therapies.

Nubeqa is a medicine used to treat men with prostate cancer. It is used when the cancer is castration-resistant (worsens despite treatment to lower testosterone levels, including surgical removal of the testes) and is at high risk of metastasis (spreading to other parts of the body). Nubeqa contains the active substance darolutamide.

November 30, 2022

https://www.fdanews.com/
0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies